Support diagnosis of neurosarcoidosis. May be used to evaluate treatment response.
Note: Gadolinium contrast agents have been reported to inhibit ACE activity. Therefore, CSF containing gadolinium-based contrast agents should not be submitted to the laboratory for evaluation.
Xanthochromic samples (yellow color)
This test was developed and its performance characteristics have been determined by ARUP Laboratories. The U.S. Food and Drug Administration has not approved or cleared this test; however, FDA clearance or approval is not currently required for clinical use. The results are not intended to be used as the sole means for clinical diagnosis or patient management decisions.